{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04900519",
            "orgStudyIdInfo": {
                "id": "47MAB-ADVCA-101"
            },
            "organization": {
                "fullName": "Sorrento Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors",
            "officialTitle": "A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-the-safety-and-efficacy-of-sti-in-subjects-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-17",
            "studyFirstSubmitQcDate": "2021-05-19",
            "studyFirstPostDateStruct": {
                "date": "2021-05-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-01-12",
            "lastUpdatePostDateStruct": {
                "date": "2023-01-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sorrento Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.",
            "detailedDescription": "This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.\n\nThe study will determine an MTD and RP2D using a conventional 3+3 study design with priming dose identification (PDI) stage and therapeutic dose (TD) escalation (TDE) stage. Dose limiting toxicity evaluated over the initial 28 days of STI-6643 administration."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor",
                "Relapsed Solid Neoplasm",
                "Refractory Tumor"
            ],
            "keywords": [
                "solid tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "STI-6643",
                    "type": "EXPERIMENTAL",
                    "description": "STI-6643 will be provided in a single use 10-mL high borosilicate type 1 glass vial at a concentration of 500mg/10 mL (50 mg/mL) administered intravenously weekly for 4 weeks, then biweekly for Cycles 2 and up.",
                    "interventionNames": [
                        "Biological: STI-6643"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "STI-6643",
                    "description": "Anti-CD47 human monoclonal antibody",
                    "armGroupLabels": [
                        "STI-6643"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety of STI-6643",
                    "description": "Safety as assessed by incidence of adverse events, SAEs, DLTs, and clinically significant changes in safety lab results",
                    "timeFrame": "Baseline through study completion at up to approximately 31 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall response rate",
                    "description": "Overall response rate",
                    "timeFrame": "Day 1 through study completion at up to approximately 31 months"
                },
                {
                    "measure": "Duration of response",
                    "description": "Duration of response",
                    "timeFrame": "Day 1 through study completion at up to approximately 31 months"
                },
                {
                    "measure": "STI-6643 receptor occupancy",
                    "description": "STI-6643 receptor occupancy",
                    "timeFrame": "Day 1 through Day 22"
                },
                {
                    "measure": "Anti-drug antibodies directed to STI-6643",
                    "description": "Anti-drug antibodies directed to STI-6643",
                    "timeFrame": "Day 1 through Day 15"
                },
                {
                    "measure": "PK parameters",
                    "description": "Evaluate the pharmacokinetics of STI-6643",
                    "timeFrame": "Day 1 through Day 22"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent\n* Age \u2265 18 years\n* ECOG Performance Status \u2264 2\n* Histologically- or cytologically-confirmed solid tumor\n* Patient has relapsed, is refractory to, or intolerant of standard of care therapy\n* No available approved therapy that may provide clinical benefit (per Investigator)\n* Measurable or evaluable disease by RECISTv1.14\n* Life expectancy of \\> 12 weeks (per Investigator)\n* Adequate laboratory parameters including:\n\n  1. Absolute neutrophil count (ANC) \u2265 1500/mm3\n  2. Platelets \u2265 100,000/mm3\n  3. Hemoglobin \u2265 12 g/dL (in the absence of transfusion over the prior 2 weeks)\n  4. AST/SGOT \u2264 2.5 x ULN (\u2264 5 x ULN if known liver involvement)\n  5. ALT/SGPT \u2264 2.5 x ULN (\u2264 5 x ULN if known liver involvement)\n  6. Total bilirubin \u2264 2.0 x ULN (unless diagnosis of Gilbert's syndrome in which case \\< 3.0 times ULN)\n  7. Serum creatinine \u2264 2.0 x ULN or estimated GFR \u2265 45 mL/min (per Cockcroft- Gault equation)\n* If residual treatment related toxicity from prior therapy:\n\n  1. Treatment related toxicity resolved to \u2264 Grade 1 (alopecia excepted), or\n  2. Treatment related toxicity resolved to \u2264 Grade 2 with prior approval of the Medical Monitor\n* Willingness to comply with the study schedule and all study requirements\n* \\[Females\\] Must be postmenopausal, surgically sterile, or agree to use adequate contraception (per Investigator) throughout the study and for a least 30 days following the last dose\n* \\[Males\\] Must be surgically sterile or must agree to use adequate contraception (per Investigator) throughout the study and for at least 30 days following the last dose\n* \\[Males\\] Willingness to refrain from donating sperm throughout the study and for at least 30 days following the last dose\n* \\[Females\\] If of child-bearing potential, must have a negative serum pregnancy test\n\nExclusion Criteria:\n\n* Participating in any other interventional clinical study\n* Previous exposure to an anti-CD47 or SIRP\u03b1 antibody\n* \u2264 28 days (or 5 half-lives if shorter) between of systemic anti-tumor treatment (e.g., chemotherapy, endocrine therapy, immunotherapy, cellular therapy) and the 1st dose of STI-6643\n* \u2264 28 days from prior irradiation (\u2264 7 days from limited field irradiation for control of symptoms) and the 1st dose of STI-6643\n* \u2264 28 days between major surgery (\u2264 7 days from minor surgical procedures, no waiting period following central catheter placement)\n* \u2264 7 days between administration of G-CSF, GM-CSF, erythropoietin, thrombopoietin or IL11 and the 1st dose of STI-6643\n* \u2264 7 days between systemic immunosuppressive therapy in excess of 10 mg/day prednisone equivalent and the 1st dose of STI-6643 (topical or inhaled corticosteroids not restricted)\n* \u2264 28 days between a live attenuated vaccine and the 1st dose of STI-6643\n* Known central nervous system (CNS) involvement with tumor (e.g., metastases, meningeal carcinomatosis)\n* Active second malignancy requiring ongoing systemic treatment\n* History of primary immunodeficiency disorders\n* History of active pulmonary tuberculosis\n* History of COVID-19 symptoms unless COVID-19 test negative \u2264 72 hours of the 1st dose of STI-6643\n* \u2264 12 weeks from an allogeneic hematopoietic stem cell transplant and C1D1 or active graft-versus-host disease (GvHD)\n* Active infection (e.g., bacterial, viral, fungal) requiring systemic treatment \u2264 72 hours of the 1st dose of STI-6643\n* Known HIV-positive with CD4+ cell counts \\< 350 cells/uL or a history of an AIDS defining opportunistic infection\n* Known T-cell leukemia virus type 1 (HTLV1) infection, hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia\n* Significant risk for HBV reactivation (defined as HbsAg positive, HbcAb positive or HBV DNA positive)\n* Detectable HCV RNA\n* Pregnant or breast feeding\n* History of clinically significant cardiovascular abnormalities including:\n\n  1. Congestive heart failure (NYHA classification \u2265 3) within 6 months of the 1st dose of STI-6643\n  2. Unstable angina pectoris\n  3. \u2264 6 months from myocardial infarction and the 1st dose of STI-6643\n  4. Arrhythmias (other than atrial fibrillation) requiring ongoing treatment\n  5. QTcF interval \\> 480 msec (using Fridericia's formula)\n  6. Uncontrolled hypertension (i.e., systolic BP \\> 180 mmHg or diastolic BP \\> 100\n* Any condition, including the presence of laboratory abnormalities, that places the subject at an unacceptable risk if the subject was to participate in the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mike Royal, MD",
                    "role": "CONTACT",
                    "phone": "(858) 203-4100",
                    "phoneExt": "4146",
                    "email": "mroyal@sorrentotherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mike Royal, MD",
                    "affiliation": "Sorrento Therapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Diego",
                    "status": "NOT_YET_RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92093",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sandip Patel, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Sanford Health",
                    "status": "RECRUITING",
                    "city": "Sioux Falls",
                    "state": "South Dakota",
                    "zip": "57104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Staci Vogel",
                            "role": "CONTACT",
                            "phone": "605-328-1368",
                            "email": "staci.vogel@sanfordhealth.org"
                        },
                        {
                            "name": "Steven Powell, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.54997,
                        "lon": -96.70033
                    }
                },
                {
                    "facility": "NEXT Oncology - Austin",
                    "status": "COMPLETED",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Timothy Eamma",
                            "role": "CONTACT",
                            "phone": "214-658-1947",
                            "email": "TEamma@marycrowley.org"
                        },
                        {
                            "name": "Reva Schneider, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carrie Friedman, RN",
                            "role": "CONTACT",
                            "email": "carrie.friedman@usoncology.com"
                        },
                        {
                            "name": "Alexander Spira, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}